Can you use HSA or FSA for tirzepatide? What is eligible

If you have a health savings account or flexible spending account, you already know the appeal: pre-tax dollars that can cut your real out-of-pocket cost by 22 to 37 percent depending on your tax bracket. The question is whether tirzepatide qualifies. The short answer is: it depends on why it is prescribed and how you document it. This post walks through the actual IRS rules, what your plan administrator will ask for, and what you need to know specifically about compounded tirzepatide.

How HSA and FSA eligibility actually works

Both HSAs and FSAs are governed by IRS Section 213(d), which allows reimbursement for expenses incurred for the 'diagnosis, cure, mitigation, treatment, or prevention of disease.' The critical word is disease. A prescription medication used to treat a recognized medical condition generally qualifies. A product used purely for general health or cosmetic purposes generally does not.

Obesity is classified as a chronic disease by the American Medical Association, the CDC, and the World Health Organization. When a licensed provider diagnoses obesity or an obesity-related condition — such as type 2 diabetes, hypertension, obstructive sleep apnea, or nonalcoholic fatty liver disease — and writes a prescription for tirzepatide as part of that treatment, the medication cost has a strong basis for HSA and FSA eligibility. The prescription itself is your primary documentation.

• HSA (Health Savings Account): paired with a high-deductible health plan; funds roll over year to year; you own the account permanently.
• FSA (Flexible Spending Account): employer-sponsored; funds typically must be used within the plan year or a short grace period; use-it-or-lose-it rules apply.
• Both accounts reimburse prescription medication costs when the medication is prescribed for a qualifying medical condition.
• Over-the-counter weight-loss supplements without a prescription do not qualify — a prescription is the dividing line.
• Telehealth consultation fees paid to a licensed medical provider also generally qualify as a medical expense under Section 213(d).

One important nuance: your plan administrator — not the IRS — makes the final call on specific claims. Some administrators are more conservative than others. Keeping a Letter of Medical Necessity (LMN) from your prescribing provider is the single best way to protect your reimbursement if a claim is questioned.

Does compounded tirzepatide specifically qualify?

This is where people get confused, so let's be precise. Tirzepatide is available in two forms: FDA-approved brand-name products (Zepbound for weight management, Mounjaro for type 2 diabetes) and compounded tirzepatide prepared by a US-licensed compounding pharmacy under a valid prescription. Compounded tirzepatide is not an FDA-approved finished drug product. It is a pharmacy-compounded preparation — legally distinct from the branded versions.

From an HSA and FSA standpoint, what matters is whether the medication was obtained with a valid prescription from a licensed provider for a qualifying medical condition. Compounded medications prescribed by a licensed physician have historically been reimbursable under HSA and FSA rules when those conditions are met. The compound status alone does not disqualify the expense. That said, plan administrators vary, and some have begun scrutinizing compounded GLP-1 claims more carefully. A Letter of Medical Necessity documenting your diagnosis and the clinical rationale for the prescription significantly strengthens your claim.

Practically speaking, here is what the reimbursement path looks like: you pay for your prescription out of pocket at the compounding pharmacy, save the itemized receipt showing the drug name, quantity, date, and prescriber information, then submit it to your HSA or FSA administrator. Some administrators also accept a superbill or explanation of benefits. Do not submit a receipt that says only 'medication' — the more detail, the better.

Why the cost question matters: what the clinical evidence shows about tirzepatide

If you are evaluating whether tirzepatide is worth the cost — with or without HSA and FSA savings — it helps to understand what the evidence actually shows. The following figures come from clinical trials of the tirzepatide molecule itself and are not StaveMD patient data.

SURMOUNT-1 (Jastreboff et al., NEJM 2022) enrolled adults with obesity or overweight plus at least one weight-related complication. At the highest dose of 15 mg weekly over 72 weeks, participants lost a mean of approximately 20.9 percent of body weight. That is not a rounding error — it represents a level of weight loss that was previously achievable only through bariatric surgery in most patients. SURMOUNT-5 compared tirzepatide head-to-head against semaglutide 2.4 mg and found tirzepatide produced roughly 20.2 percent weight loss versus 13.7 percent for semaglutide over 72 weeks.

Why does this happen? Tirzepatide acts on two hormone receptors: GIP and GLP-1. Both are involved in appetite regulation, satiety signaling, and metabolic function. When these receptors are activated, the result is a significant reduction in appetite and in what many patients describe as food noise — the constant, intrusive mental chatter about food that has nothing to do with willpower and everything to do with biology. Research on metabolic adaptation, including the NIH-funded Biggest Loser study (Fothergill et al., 2016), demonstrated that the body actively fights weight loss by suppressing metabolic rate and amplifying hunger hormones. That is not a character flaw. It is a measurable physiological response. Medications like tirzepatide work at that biological level.

• SURMOUNT-1 mean weight loss: approximately 20.9% at 15 mg over 72 weeks — tirzepatide molecule trial data, not StaveMD patient data.
• SURMOUNT-5 comparison: tirzepatide -20.2% vs. semaglutide -13.7% — tirzepatide molecule trial data, not StaveMD patient data.
• Common side effects include nausea, constipation, diarrhea, and vomiting, most often during dose escalation.
• Results vary significantly between individuals — some lose more, some less; the trial figures are group averages.
• Tirzepatide is not appropriate for everyone, including those with a personal or family history of medullary thyroid carcinoma or MEN 2.

Practical steps to use your HSA or FSA for tirzepatide

Before you pay anything, take ten minutes to do the following. First, call your HSA or FSA administrator and ask directly whether compounded prescription medications are covered under your plan. Get the name of the representative and make a note of what they say. Second, ask your prescribing provider for an itemized receipt and a Letter of Medical Necessity that specifies your diagnosis and the medical rationale for tirzepatide. Third, check whether your administrator accepts direct payment to the pharmacy or requires you to pay and submit for reimbursement. Most require reimbursement submission for compounding pharmacies that are not in their network.

For FSA users specifically: be aware of your plan year deadline. If you have funds expiring at the end of the year and you are already in treatment, ongoing prescription refills and consultation fees can be submitted before the deadline. Do not leave pre-tax money on the table because of a paperwork delay.

Telehealth consultation fees are also typically eligible. The fee you pay StaveMD for a provider visit is a medical service charge and generally qualifies under Section 213(d) the same way an in-person office visit would. Check your plan's specific rules, but this is an often-overlooked eligible expense.

• Call your administrator before your first purchase to confirm compounded medication eligibility under your specific plan.
• Request a Letter of Medical Necessity from your provider — this is your best protection if a claim is questioned.
• Save itemized receipts showing drug name, date, prescriber name, and amount paid.
• Submit telehealth consultation fees as a separate eligible expense.
• FSA users: track your plan year deadline and submit claims before funds expire.

The bottom line is that using HSA or FSA funds for tirzepatide is genuinely possible for many people and can reduce your effective cost by hundreds of dollars over a course of treatment. The eligibility hinges on having a valid prescription for a recognized medical condition and documentation to support your claim. Those are reasonable hurdles — and they are exactly the kind of things a licensed telehealth provider can help you put in place.